Albicin is under clinical development by Nielsen Biosciences and currently in Phase III for Warts. According to GlobalData, Phase III drugs for Warts have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Albicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Albicin is under development for the treatment of warts caused by human papillomavirus and delayed-type hypersensitivity (DTH) response at the injection site . It is administered through intralesional and intradermal routes. It is a solution derived from Candida albicans.
Nielsen Biosciences overview
Nielsen Biosciences is a biotechnology company that develops cellular immunity drugs. The company develops CANDIN, a candida albicans skin test antigen for cellular immunity used in intradermal injection for detecting delayed-type hypersensitivity. Nielsen Biosciences provides SPHERUSOL, a s kin test antigen to detect and monitor the cell-mediated immune response to coccidioides in patients with valley fever. The company also offers evaluation of CANDIN in ongoing investigational studies for use in the treatment of human papilloma virus HPV lesions. Nielsen Biosciences is headquartered in San Diego, California, the US.
For a complete picture of Albicin’s drug-specific PTSR and LoA scores, buy the report here.